Evidence map›Paper›PMID 25306203›Full record

ArticleSchizophrenia research2015

The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2.

Bruce I Turetsky, Erich M Dress, David L Braff, Monica E Calkins, Michael F Green, Tiffany A Greenwood, Raquel E Gur, Ruben C Gur, Laura C Lazzeroni, Keith H Nuechterlein and 11 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 124 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. P300 in schizophrenia: Then and now.Biological psychology · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

Bruce I TuretskyDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: turetsky@upenn.edu.
Erich M DressDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
David L BraffDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, USA.
Monica E CalkinsDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Michael F GreenDepartment of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Tiffany A GreenwoodDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Raquel E GurDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Ruben C GurDepartment of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Laura C LazzeroniDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.
Keith H NuechterleinDepartment of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Allen D RadantDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA, USA.
Larry J SeidmanDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, MA, USA.
Larry J SieverDepartment of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA; James J. Peters VA Medical Center, New York, NY, USA.
Jeremy M SilvermanDepartment of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA; James J. Peters VA Medical Center, New York, NY, USA.
Joyce SprockDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
William S StoneDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, MA, USA.
Catherine A SugarDepartment of Biostatistics, University of California Los Angeles School of Public Health, Los Angeles, CA, USA.
Neal R SwerdlowDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Debby W TsuangDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA, USA.
Ming T TsuangDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; Center for Behavioral Genomics and Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA; Harvard Institute of Psychiatric Epidemiology and Genetics, Boston, MA, USA.
Gregory LightDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, USA.
University of Pennsylvania · USUniversity of California, San Diego · USUniversity of California, Los Angeles · USUniversity of Washington · USHarvard University · USIcahn School of Medicine at Mount Sinai · USJames J. Peters VA Medical Center · USMassachusetts Mental Health Center · USMental Illness Research, Education and Clinical Centers · USStanford University · USVA San Diego Healthcare System · US

Funding

The Genetics of Endophenotypes and SchizophreniaR01MH065571 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 2003 to 2013
$7.0M
The Genetics of Endophenotypes and SchizophreniaR01MH065578 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 2003 to 2013
$4.2M
The Genetics of Endophenotypes and SchizophreniaR01MH065554 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SIEVER, LARRY J · 2003 to 2013
$4.1M
Genetics of Endophenotypes and SchizophreniaR01MH065558 · NIMH · UNIVERSITY OF WASHINGTON · PI TSUANG, DEBBY WEN · 2003 to 2013
$3.7M
The Genetics of Endophenotypes and SchizophreniaR01MH065707 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GREEN, MICHAEL F. · 2003 to 2013
$3.6M
6/6 - The Genetics of Endophenotypes and SchizophreniaR01MH086135 · NIMH · STANFORD UNIVERSITY · PI LAZZERONI, LAURA C. · 2010 to 2013
$1.3M
NIMH NIH HHS MH065554NIMH NIH HHS MH065558NIMH NIH HHS MH065571NIMH NIH HHS MH065578NIMH NIH HHS MH065707NIMH NIH HHS MH86135NIMH NIH HHS R01 MH065554NIMH NIH HHS R01 MH065558NIMH NIH HHS R01 MH065571NIMH NIH HHS R01 MH065578NIMH NIH HHS R01 MH065707NIMH NIH HHS R01 MH086135
6 · The paper itself

Abstract

Reduced auditory P300 amplitude is a robust schizophrenia deficit exhibiting the qualities of a viable genetic endophenotype. These include heritability, test-retest reliability, and trait-like stability. Recent evidence suggests that P300 may also serve as a predictive biomarker for transition to psychosis during the schizophrenia prodrome. Historically, the utility of the P300 has been limited by its clinical nonspecificity, cross-site measurement variability, and required EEG expertise. The Consortium on the Genetics of Schizophrenia (COGS-2) study provided an opportunity to examine the consistency of the measure across multiple sites with varying degrees of EEG experience, and to identify important modulating factors that contribute to measurement variability. Auditory P300 was acquired from 649 controls and 587 patients at 5 sites. An overall patient deficit was observed with effect size 0.62. Each site independently observed a significant patient deficit, but site differences also existed. In patients, site differences reflected clinical differences in positive symptomatology and functional capacity. In controls, site differences reflected differences in racial stratification, smoking and substance use history. These factors differentially suppressed the P300 response, but only in control subjects. This led to an attenuated patient-control difference among smokers and among African Americans with history of substance use. These findings indicate that the P300 can be adequately assessed quantitatively, across sites, without substantial EEG expertise. Measurements are suitable for both genetic endophenotype analyses and studies of psychosis risk and conversion. However, careful attention must be given to selection of appropriate comparison samples to avoid misleading false negative results.

Indexed as

EndophenotypesEvent-Related Potentials, P300AdultAuditory PerceptionBiomarkersBlack or African AmericanBrainElectroencephalographyFemaleHumansMaleMiddle AgedNeuropsychological TestsProdromal SymptomsPrognosisPsychiatric Status Rating ScalesBiomarkersBiomarkerEndophenotypeEvent-related potentialP300Schizophrenia

Identifiers

PMID25306203
PMCPMC4382423
OpenAlexW2083825254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.